` 1C0 (Celyad Oncology SA) vs DAX Index Comparison - Alpha Spread

1C0
vs
D
DAX Index

Over the past 12 months, 1C0 has significantly outperformed DAX Index, delivering a return of +86% compared to the DAX Index's +36% growth.

Stocks Performance
1C0 vs DAX Index

Loading
1C0
DAX Index
Add Stock
www.alphaspread.com

Performance Gap
1C0 vs DAX Index

Loading
1C0
DAX Index
Difference
www.alphaspread.com

Performance By Year
1C0 vs DAX Index

Loading
1C0
DAX Index
Add Stock

Competitors Performance
Celyad Oncology SA vs Peers

DAX Index
1C0
ABBV
AMGN
GILD
VRTX
Add Stock

Celyad Oncology SA
Glance View

Market Cap
4.3m EUR
Industry
Biotechnology

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 88 full-time employees. The company went IPO on 2013-07-05. The firm is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The firm develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The firm's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). The company also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).

1C0 Intrinsic Value
0.057 EUR
Overvaluation 84%
Intrinsic Value
Price
Back to Top